newYou can listen to Fox’s news articles!
The Trump administration has expressed interest in exploring psychedelics about their potential in treating PTSD and other debilitating conditions Mental health issuesshared by various officials.
“The department shares the goal of ensuring that all Americans, particularly veterans in our country, have access to safe and effective treatment for conditions such as PTSD, addiction, depression, and more. Robert J. Kennedy Jr. said in a statement provided to Fox News Digital.
“Committee Kennedy is committed to applying rigorous, evidence-based science to these serious research efforts. Health challenges. ”
FDA approves first AI tools to predict breast cancer risk
In recent years, researchers have been actively investigating the possibilities of psychedelics such as MDMA and psilocybin (“Magic Mushroom“) Treat mental health disorders.
MDMA is not approved for clinical use by the US Food and Drug Administration (FDA), but can be studied in a clinical setting.
Psychedelic research has received support from the Trump administration to treat PTSD and mental health conditions. (istock)
Psilocybin is listed as a Schedule I substance under the Controlled Substances Act. That is, “there is a high possibility of abuse, [is not] Currently, medical use in treatment in the United States is permitted, [has] Lack of accepted safety for use under medical supervision. ”
However, psilocybin-assisted therapy is legal in Oregon, Colorado and New Mexico.
“Showing a promise”
Psychedelic drugs “show us a real promise,” according to Dr. Luke Twelves, vice president of medical care at Lindus Health in London.
Clinical trials have found such treatments to be safe and effective for patients fighting a serious struggle Mental health According to question, 12.
Common supplements and medications can cause liver damage, studies show
“Take psilocybin, for example. It shows significant consequences of severe depression that are not responding to other medications,” he told Fox News Digital. “MDMA shows a similar breakthrough PTSD treatment. ”
Clinical trials investigate how psychedelics can help end-of-life anxiety and addiction Eating disorderschronic pain and OCD, he added.
In recent years, researchers have been actively investigating the potential of psychedelics such as MDMA and psilocybin to treat mental disorders. (istock)
Researchers face challenges in terms of regulatory hurdles and appropriate placebo control, Twelbes said.
“Given the possibility that these treatments may change [the] “It is important that this study be properly completed in the lives of people who are struggling with situations where nothing else is working effectively,” he said.
Possibility of Veterans
President Trump’s May 1 Cabinet meeting, division Veterans “We are open to the possibilities of psychedelic treatment,” said Secretary Doug Collins.
Retirement Army Sgt. Jonathan Lubecki recently told Fox News’ Alexandria Hoff that MDMA had stopped PTSD while participating in clinical trials.
VA is now open to the possibilities of psychedelic treatments to promote the health of veterans. (istock)
“[I] I took my first MDMA. I’ve only taken three times as part of a clinical trial and haven’t taken it since, but I don’t have PTSD so I haven’t found the need to take it,” he said.
Veterans Executive Director Peter Casperowicz told Fox News Digital that he is safely exploring all paths that promote veteran health.
“The preliminary findings have yielded positive results for psychedelic assisted therapy to treat mental health conditions,” he said.
VA is currently running 11 times Clinical trials It is expected that a total of approximately 800 veterans will participate at various stages.
Click here to get the Fox News app
“The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depression disorder, major depressive disorder, and potentially other psychological factors. Health status” said Kasperovic.
Psilocybin is a Schedule I drug under the Controlled Substances Act, but psilocybin-assisted therapy is legal in Oregon, Colorado and New Mexico. (istock)
An MDMA study published in the January 2025 issue of the American Journal of Psychiatry found that the substance “different from classical psychedelics.”
The study states, “MDMA allows individuals to maintain their intact ego function. The cognitive and perceptual clarity while still experiencing the state of consciousness of prosocial change that promotes deep emotional therapeutic breakthroughs. ”
Click here to sign up for our health newsletter
Researchers concluded that MDMA showed a lack of “trust, empathy, self-compassion, and “windows of tolerance” in traditional psychotherapy.
VA is currently undergoing 11 psychedelic clinical trials at various stages. (istock)
“It’s time to deal with the mental health crisis,” Doug Drysdale, CEO of Canadian pharmaceutical company Cybin, told Fox News Digital.
He said it was “satisfactory” that administration officials are assessing the potential benefits of considering alternative mental health treatments.
“It’s time to deal with the mental health crisis.”
Cybin is currently in the third stage of Cyb003’s research. This has been granted the breakthrough therapy designation by the FDA, and the FDA has been granted as an additional treatment. Major depressive disorder (MDD).
“A complete Phase 2 MDD study of cybin showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment 12 months after a dose of just 16 mg of Cyb003,” Drysdale said.
Risks and warnings
Dr. Marc Siegel, Professor of Clinical Medicine Nyu Langone Medical Center And senior medical analysts at Fox News previously interviewed two top psychedelic researchers. Dr. Charles Mahmer, founder and founder of Psychedelic Psychotherapy and Mount Sinai in New York and director of Nyu Langone’s PTSD Research Program.
“There are major drawbacks when it comes to unregulated recreational uses.”
“They agree that there is a potential for treatment if they are being studied very carefully under very strict medical guidance, but there are major downsides when it comes to unregulated recreational uses,” Siegel told Fox News Digital at the time.
Experts emphasize the importance of managing psychedelics in a safe environment when treating mental health conditions. (istock)
“Both physicians are likely to see therapeutic value for psychedelics when carefully managed. Medical professionals“Siegel added.
Ryan Moss, chief science officer at Filament Health, a Canadian clinical stage natural psychedelic drug developer, emphasized the importance of administering psychedelics in a safe environment when treating mental health conditions.
Visit us for more health articles www.foxnews.com/health
“Psychedelic experiences can be characterized by anxiety, hallucinations and delusions,” Moss previously told Fox News Digital. “Some patients who use traditional psychedelics have had adverse experiences, some patients have Cardiovascular events Under clinical trials. ”
To mitigate these risks, Moss recommended participants in clinical trials who received thorough preparation and monitoring by trained experts during the session.
Melissa Rudy and Angelica Stabile of Fox News Digital contributed to the report.
